How have INVO shares performed in 2024?

INVO Bioscience's stock was trading at $1.35 at the beginning of 2024. Since then, INVO shares have increased by 12.6% and is now trading at $1.52. View the best growth stocks for 2024 here .

Are investors shorting INVO Bioscience?

INVO Bioscience saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,100 shares, an increase of 10.0% from the March 15th total of 11,000 shares. Based on an average daily trading volume, of 27,500 shares, the short-interest ratio is presently 0.4 days. Approximately 0.5% of the shares of the stock are sold short. View INVO Bioscience's Short Interest .

When is INVO Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our INVO earnings forecast .

How were INVO Bioscience's earnings last quarter?

INVO Bioscience, Inc. (NASDAQ:INVO) issued its quarterly earnings results on Monday, November, 15th. The company reported ($4.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.00) by $0.80. The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter in the prior year, the business earned ($7.20) earnings per share.

When did INVO Bioscience's stock split?

Shares of INVO Bioscience reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of INVO Bioscience?

Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INVO

INVO Bioscience (INVO) Stock Price, News & Analysis

→ The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad)

Free INVO Stock Alerts

$1.52

-0.30 (-16.48%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.33
▼
$1.71
50-Day Range: $0.77
▼
$1.82
52-Week Range: $0.50
▼
$10.50

Volume: 5.04 million shs
Average Volume: 3.17 million shs
Market Capitalization: $3.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get INVO Bioscience alerts:

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About INVO Bioscience Stock (NASDAQ:INVO)

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.

INVO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INVO Stock News Headlines

April 17, 2024 | msn.com

Micro Cap Massively Bid Up Before Opening Bell

April 17, 2024 | benzinga.com

Why Invo BioScience Stock Is Soaring Today

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 17, 2024 | msn.com

Why Is Invo Bioscience (INVO) Stock Up 85% Today?

April 17, 2024 | investorplace.com

Why Is Invo Bioscience (INVO) Stock Up 85% Today?

April 17, 2024 | benzinga.com

Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket

April 17, 2024 | finance.yahoo.com

Aadi Bioscience, Inc. (AADI) Latest Stock News & Headlines - Yahoo Finance

April 16, 2024 | msn.com

INVO Stock Earnings: INVO Bioscience Reported Results for Q4 2023

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

April 16, 2024 | finance.yahoo.com

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

April 16, 2024 | americanbankingnews.com

Short Interest in INVO Bioscience, Inc. (NASDAQ:INVO) Expands By 10.0%

April 4, 2024 | seekingalpha.com

ASMB Assembly Biosciences, Inc.

February 22, 2024 | benzinga.com

INVO Bioscience Stock (NASDAQ:INVO), Short Interest Report

February 4, 2024 | morningstar.com

INVO Bioscience Inc INVO

January 23, 2024 | marketwatch.com

INVO BioScience Shares Up 5% as NAYA Agrees to Buy Florida Biotechnologies

January 23, 2024 | finance.yahoo.com

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

January 23, 2024 | finance.yahoo.com

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

January 17, 2024 | finance.yahoo.com

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

December 23, 2023 | finance.yahoo.com

INVO Bioscience, Inc. (INVO) Stock Historical Prices & Data - Yahoo Finance

December 11, 2023 | finance.yahoo.com

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

December 6, 2023 | msn.com

NAYA, ONK team up to evaluate potential cancer therapy combinations

December 6, 2023 | finance.yahoo.com

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

November 28, 2023 | finance.yahoo.com

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

November 14, 2023 | benzinga.com

Why INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving Premarket

November 13, 2023 | finance.yahoo.com

INVO Reports Record Third Quarter 2023 Financial Results

November 13, 2023 | msn.com

What's Going On With INVO BioScience Stock?

November 13, 2023 | finance.yahoo.com

BestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences Merger

See More Headlines

Receive INVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:INVO
CUSIP: N/A
CIK: 1417926
Web: www.invobioscience.com
Phone: (978) 878-9505
Fax: N/A
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($12.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,890,000.00
Net Margins: -459.42%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -88.87%

Debt

Debt-to-Equity Ratio: 2.94
Current Ratio: 0.37
Quick Ratio: 0.31

Sales & Book Value

Annual Sales: $3.02 million
Price / Sales: 1.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.61) per share
Price / Book: -0.88

Miscellaneous

Outstanding Shares: 2,470,000
Free Float: 2,388,000
Market Cap: $3.51 million
Optionable: No Data
Beta: 1.45

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Steven M. Shum (Age 53)
CEO & Director
Comp: $260k
Mr. Andrea Goren (Age 57)
Chief Financial Officer
Comp: $215k
Mr. Michael Jos. Campbell (Age 66)
COO & VP of Business Development
Comp: $220k
Mr. Bojan Mitrovic Ph.D.
Director of Sales US
Mr. Robert Joseph Bowdring Jr. (Age 66)
Treasurer & Secretary
Ms. Terah Krigsvold
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

INVO Stock Analysis - Frequently Asked Questions

How have INVO shares performed in 2024?: INVO Bioscience's stock was trading at $1.35 at the beginning of 2024. Since then, INVO shares have increased by 12.6% and is now trading at $1.52.
View the best growth stocks for 2024 here.
Are investors shorting INVO Bioscience?: INVO Bioscience saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,100 shares, an increase of 10.0% from the March 15th total of 11,000 shares. Based on an average daily trading volume, of 27,500 shares, the short-interest ratio is presently 0.4 days. Approximately 0.5% of the shares of the stock are sold short.
View INVO Bioscience's Short Interest.
When is INVO Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our INVO earnings forecast.
How were INVO Bioscience's earnings last quarter?: INVO Bioscience, Inc. (NASDAQ:INVO) issued its quarterly earnings results on Monday, November, 15th. The company reported ($4.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.00) by $0.80. The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter in the prior year, the business earned ($7.20) earnings per share.

When did INVO Bioscience's stock split?: Shares of INVO Bioscience reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of INVO Bioscience?: Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INVO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial